Q2 2025 Financial Performance - Organic sales grew by 1%[20] - Adjusted EBITDA margin decreased by 40 bps[20] - Free cash flow increased by 25%[20] - Organic orders increased by 2% year-over-year[20] Segment Performance - Health & Science Technologies (HST) organic sales grew by 4%[23], with orders up by 2%[23] - Fluid & Metering Technologies (FMT) organic sales decreased by 2%[29], but orders increased by 7%[29] - Fire & Safety/Diversified Products (FSDP) organic sales grew by 2%[34], but orders decreased by 7%[34] 2025 Guidance - The company expects approximately 1% organic revenue growth for the full year[39] - The company expects 2%-3% organic revenue growth for the third quarter[39] - Adjusted EBITDA is projected to be between 265% and 270% for the full year[39] - Adjusted earnings per share are estimated to be between $785 and $795 for the full year[39]

Financial Performance - First quarter sales increased by 2% year-over-year, from $800.5 million to $814.3 million[18, 80] - Organic sales decreased by 1%[19] - Adjusted EBITDA margin decreased by 50 bps, from 26% to 25.5%[18] - Adjusted EPS decreased by 7%, from $1.88 to $1.75[18] - Free cash flow decreased by 33%, from $136.6 million to $91.4 million[18, 82] Segment Results - Health & Science Technologies (HST) sales increased by 10%, with organic sales down by 1%[27] - Fluid & Metering Technologies (FMT) sales decreased by 7%, with organic sales down by 4%[33] - Fire & Safety/Diversified Products (FSDP) sales increased by 4%, with organic sales up by 5%[42] Guidance - The company expects organic revenue to increase by 1% to 3% for the full year 2025[49] - The company expects adjusted EBITDA to be 27.5% to 28.0% for the full year 2025[49] - The company expects adjusted EPS to be $8.10 to $8.45 for the full year 2025[49] Tariff Impact - The total annualized tariff impact is estimated to be approximately $100 million[54]

Group 1: Company Performance - IDEX Corporation (IEX) is experiencing solid momentum in the Fluid & Metering Technologies segment, with organic revenues increasing by 3% year-over-year in Q4 2024. The company anticipates overall organic revenues to rise by 1-3% year-over-year in 2025 [1] - The Health & Science Technologies segment is facing challenges, with organic revenues declining by 7% year-over-year in 2024 and remaining flat in Q4 [7] - Rising selling, general, and administrative expenses are impacting IDEX's bottom line, increasing by 14% year-over-year in Q4 2024, with costs of sales also rising by 9.7% [8] Group 2: Acquisitions and Growth Strategy - IDEX is focused on expanding its business through acquisitions, having acquired Mott Corporation for $1 billion in September 2024, enhancing its capabilities in applied materials science technology [2] - In December 2023, IDEX completed the acquisition of STC Material Solutions for $206 million, further strengthening its expertise in material sciences [3] - Acquisitions positively impacted sales by 6% in Q4 2024, indicating a successful integration of new businesses [3] Group 3: Shareholder Returns - Management is committed to rewarding shareholders, having paid dividends totaling $205.3 million in 2024, which is a 7.7% increase year-over-year [4] - The quarterly dividend rate was increased by 7.8% in May 2024, reflecting the company's focus on returning value to shareholders [4]

Group 1: Company Performance and Segments - IDEX Corporation (IEX) is expected to benefit from the strength in the Fluid & Metering Technologies segment, with organic revenues increasing by 3% year-over-year in Q4 2024 and an anticipated overall organic revenue growth of 1-3% in 2025 [1] - The company acquired Mott Corporation for $1 billion in September 2024, enhancing its applied materials science technology capabilities and micro-precision technology offerings in key markets [2] - In December 2023, IEX acquired STC Material Solutions for $206 million, which expanded its expertise in material sciences, contributing positively to sales by 6% in Q4 2024 [3] Group 2: Shareholder Returns - IEX has been committed to rewarding shareholders, with dividend payments totaling $205.3 million in 2024, reflecting a 7.7% year-over-year increase, and a 7.8% hike in its quarterly dividend rate announced in May 2024 [4] Group 3: Financial Challenges - The company faced escalating operating expenses, with a 9.7% year-over-year increase in the cost of sales and a 14% rise in selling, general, and administrative expenses in Q4 2024, leading to a 90 basis points increase in these expenses as a percentage of sales to 22.9% [7] - Weakness in the Health & Science Technologies segment due to softness in life sciences, analytical instrumentation, automotive, and semiconductor capital equipment markets raises concerns [6]